Anti-von Willebrand factor aptamer ARC1779 for refractory thrombotic thrombocytopenic purpura

被引:50
作者
Knoebl, Paul
Jilma, Bernd [1 ]
Gilbert, James C.
Hutabarat, Renta M.
Wagner, Patricia G.
Jilma-Stohlawetz, Petra
机构
[1] Med Univ Vienna, Dept Clin Pharmacol, Dept Internal Med 1, Div Hematol & Hemostasis, A-1090 Vienna, Austria
关键词
PLASMA-EXCHANGE; RITUXIMAB;
D O I
10.1111/j.1537-2995.2009.02232.x
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
BACKGROUND: Plasma exchange is the main therapy for thrombotic thrombocytopenic purpura (TTP). No treatments other than plasma exchange have been documented to be effective nor are approved for treatment of TTP. The anti-von Willebrand factor (VWF) aptamer ARC1779 effectively inhibits VWF activity in plasma samples of TTP patients and thus shear-dependent platelet (PLT) function as measured by the PLT function analyzer PFA-100 (Dade Behring). It was hypothesized that ARC1779 would offer a potentially effective treatment option for a critically ill patient, refractory to standard care. CASE REPORT: A 39-year-old male patient with idiopathic TTP, refractory to daily plasma exchange, rituximab, steroids, and splenectomy, was additionally treated with a continuous infusion of the anti-von Willebrand factor (VWF) aptamer ARC1779 for 3 weeks. RESULTS: Plasma concentrations of approximately 10 mu g/mL ARC1779 decreased VWF activity by more than 96%. Plasma exchange treatment acutely decreased the plasma concentrations of ARC1779 by a mean of 47% (range, 40%-61%). Thus, additional minibolus infusions of ARC1779 were given after each plasma exchange to rapidly restore steady-state concentrations. ARC1779 resulted in an increase of PLT counts as long as ARC1779 was given. On three occasions the infusion was stopped, each accompanied by a decrease in PLT counts and worsening of microangiopathy. No serious adverse effects were observed during the treatment with ARC1779. CONCLUSION: ARC1779 caused a clear and reproducible increase in PLT counts in an otherwise refractory TTP case. These clinical, pharmacokinetic, and pharmacodynamic data provide a rational basis for clinical trials with ARC1779 in TTP.
引用
收藏
页码:2181 / 2185
页数:5
相关论文
共 12 条
[1]  
BobbioPallavicini E, 1997, HAEMATOLOGICA, V82, P429
[2]   First-in-human evaluation of anti-von Willebrand factor therapeutic aptamer ARC1779 in healthy volunteers [J].
Gilbert, James C. ;
DeFeo-Fraulini, Tia ;
Hutabarat, Renta M. ;
Horvath, Christopher J. ;
Merlino, Patricia G. ;
Marsh, H. Nicholas ;
Healy, Judith M. ;
BouFakhreddine, Sleiman ;
Holohan, Thomas V. ;
Schaub, Robert G. .
CIRCULATION, 2007, 116 (23) :2678-2686
[3]   Addition of rituximab to standard therapy improves response rate and progression-free survival in relapsed or refractory thrombotic thrombocytopenic purpura and autoimmune haemolytic anaemia [J].
Heidel, Florian ;
Lipka, Daniel B. ;
von Auer, Charis ;
Huber, Christoph ;
Scharrer, Inge ;
Hess, Georg .
THROMBOSIS AND HAEMOSTASIS, 2007, 97 (02) :228-233
[4]  
Hovinga JAK, 2004, HAEMATOLOGICA, V89, P320
[5]   The aptamer ARC1779 potently and specifically inhibits the excessive von Willebrand factor (vWF) activity and vWF-mediated ex vivo platelet function of patients with thrombotic thrombocytopenic purpura (TTP) [J].
Jilma, Bernd ;
Mayr, Florian B. ;
Knoebl, Paul ;
Spiel, Alexander O. ;
Mertino, Patricia G. ;
Schaub, Robert ;
Gilbert, James C. .
BLOOD, 2007, 110 (11) :89A-89A
[6]   Novel monoclonal antibody-based enzyme immunoassay for determining plasma levels of ADAMTS13 activity [J].
Kato, Seiji ;
Matsumoto, Masanori ;
Matsuyama, Tomomi ;
Isonishi, Ayami ;
Hiura, Hisahide ;
Fujimura, Yoshihiro .
TRANSFUSION, 2006, 46 (08) :1444-1452
[7]   Cognitive deficits after recovery from thrombotic thrombocytopenic purpura [J].
Kennedy, April S. ;
Lewis, Qurana F. ;
Scott, James G. ;
Hovinga, Johanna A. Kremer ;
Laemmle, Bernhard ;
Terrell, Deirdra R. ;
Vesely, Sara K. ;
George, James N. .
TRANSFUSION, 2009, 49 (06) :1092-1101
[8]   Long-term deficits in health-related quality of life after recovery from thrombotic thrombocytopenic purpura [J].
Lewis, Qurana F. ;
Lanneau, Marion S. ;
Mathias, Susan D. ;
Terrell, Deirdra R. ;
Vesely, Sara K. ;
George, James N. .
TRANSFUSION, 2009, 49 (01) :118-124
[9]   Twice-daily plasma exchange for patients with refractory thrombotic thrombocytopenic purpura: the experience of the Oklahoma Registry, 1989 through 2006 [J].
Nguyen, Loan ;
Li, Xiaoning ;
Duvall, Deanna ;
Terrell, Deirdra R. ;
Vesely, Sara K. ;
George, James N. .
TRANSFUSION, 2008, 48 (02) :349-357
[10]   COMPARISON OF PLASMA-EXCHANGE WITH PLASMA INFUSION IN THE TREATMENT OF THROMBOTIC THROMBOCYTOPENIC PURPURA [J].
ROCK, GA ;
SHUMAK, KH ;
BUSKARD, NA ;
BLANCHETTE, VS ;
KELTON, JG ;
NAIR, RC ;
SPASOFF, RA .
NEW ENGLAND JOURNAL OF MEDICINE, 1991, 325 (06) :393-397